◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › DXCM

DexCom Inc (DXCM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Health Care Equipment · DATA UPDATED 2026-07-16

DexCom Inc (DXCM) operates in the Health Care Equipment industry and is headquartered in San Diego, United States with about 11,000 employees. Its market capitalization is roughly $28 billion. In the fiscal year ended 2025-12-31, DXCM reported $4.7B in revenue and $836M in net income.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

Interactive charts & full statements → Open the DXCM valuation workbench →

DXCM Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.8B	$4.7B	$4.0B	$3.6B	$2.9B	$2.4B	$1.9B	$1.5B	$1.0B	$718M	$573M	$402M	$259M	$160M	$100M	$76M	$49M	$30M	$10M	$5M	$2M
Gross Profit	$3.0B	$2.8B	$2.4B	$2.3B	$1.9B	$1.7B	$1.3B	$932M	$664M	$492M	$378M	$278M	$176M	$100M	$47M	$36M	$18M	$4M	($6M)	($8M)	($9M)
Gross Margin %	61.8%	60.0%	60.5%	63.2%	64.7%	68.6%	66.4%	63.1%	64.4%	68.5%	66.0%	69.2%	68.0%	62.6%	46.7%	47.0%	37.9%	12.3%	-56.2%	-175.2%	-405.1%
Operating Income (EBIT)	$1.0B	$912M	$600M	$598M	$391M	$266M	$300M	$142M	($186M)	($42M)	($64M)	($57M)	($22M)	($29M)	($56M)	($45M)	($45M)	($46M)	($53M)	($47M)	($49M)
Operating Margin %	21.4%	19.6%	14.9%	16.5%	13.4%	10.9%	15.5%	9.6%	-18.1%	-5.9%	-11.2%	-14.2%	-8.3%	-18.1%	-55.8%	-58.8%	-93.1%	-154.4%	-537.0%	-1008.8%	-2273.0%
Net Income	$930M	$836M	$576M	$542M	$341M	$217M	$494M	$101M	($127M)	($50M)	($66M)	($58M)	($22M)	($30M)	($54M)	($45M)	($55M)	($54M)	($55M)	($46M)	($47M)
Net Margin %	19.3%	17.9%	14.3%	14.9%	11.7%	8.9%	25.6%	6.9%	-12.3%	-7.0%	-11.4%	-14.3%	-8.6%	-18.6%	-54.5%	-58.7%	-113.5%	-180.3%	-560.9%	-991.5%	-2147.6%
EBITDA	$1.5B	$1.4B	$946M	$917M	$565M	$378M	$377M	$213M	($75M)	($20M)	($49M)	($46M)	($13M)	($22M)	($49M)	($41M)	($51M)	($43M)	($50M)	($43M)	($47M)
Earnings Per Share (EPS)	$2.31	$2.06	$1.40	$1.27	$0.80	$0.51	$1.27	$0.27	$-0.36	$-0.15	$-0.20	$-0.18	$-0.07	$-0.10	$-0.20	$-0.17	$-0.24	$-0.30	$-0.47	$-0.41	$-0.43
Shares Outstanding (M)	394M	406M	413M	426M	428M	429M	390M	369M	353M	345M	334M	319M	301M	284M	275M	262M	228M	177M	118M	113M	109M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DXCM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.2B	$1.3B	$1.2B	$1.2B	$1.0B	$1.1B	$994M	$1.0B
Gross Profit	$750M	$793M	$747M	$689M	$589M	$656M	$594M	$627M
Gross Margin %	62.9%	62.9%	61.8%	59.5%	56.9%	58.9%	59.7%	62.4%
Operating Income (EBIT)	$255M	$323M	$242M	$213M	$134M	$189M	$152M	$158M
Operating Margin %	21.4%	25.6%	20.1%	18.4%	12.9%	17.0%	15.3%	15.7%
Net Income	$200M	$267M	$284M	$180M	$105M	$152M	$135M	$144M
Net Margin %	16.7%	21.2%	23.5%	15.5%	10.2%	13.6%	13.5%	14.3%
EBITDA	$337M	$410M	$421M	$309M	$219M	$274M	$237M	$245M
Earnings Per Share (EPS)	$0.51	$0.67	$0.70	$0.44	$0.26	$0.37	$0.33	$0.34
Shares Outstanding (M)	394M	399M	407M	408M	408M	407M	410M	417M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DXCM Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$1.8B	$1.4B	$990M	$748M	$670M	$442M	$476M	$314M	$123M	$92M	$56M	$49M	$24M	$2M	($33M)	($30M)	($43M)	($39M)	($37M)	($33M)	($44M)
Capital Expenditures (CapEx)	$353M	$364M	$359M	$237M	$365M	$389M	$199M	$180M	$67M	$66M	$56M	$33M	$16M	$8M	$10M	$8M	$7M	$3M	$2M	$3M	$3M
Free Cash Flow (FCF)	$1.4B	$1.1B	$631M	$512M	$305M	$53M	$277M	$134M	$56M	$26M	$0M	$16M	$7M	($6M)	($43M)	($38M)	($50M)	($42M)	($40M)	($37M)	($47M)
FCF Margin %	29.7%	23.1%	15.6%	14.1%	10.5%	2.2%	14.4%	9.1%	5.4%	3.6%	0.1%	3.9%	2.9%	-3.4%	-42.6%	-50.0%	-101.9%	-142.7%	-406.0%	-792.1%	-2170.1%
Dividends Paid	—	—	—	$1.2B	—	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DXCM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$526M	$294M	$660M	$303M	$184M	$301M	$200M	$279M
Capital Expenditures (CapEx)	$77M	$102M	$80M	$94M	$87M	$125M	$111M	$66M
Free Cash Flow (FCF)	$449M	$192M	$579M	$209M	$97M	$177M	$88M	$213M
FCF Margin %	37.7%	15.2%	47.9%	18.1%	9.3%	15.9%	8.9%	21.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DXCM Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$6.6B	$6.3B	$6.5B	$6.3B	$5.4B	$4.9B	$4.3B	$2.4B	$1.9B	$904M	$403M	$292M	$185M	$122M	$106M	$120M	$77M	$47M	$44M	$77M	$65M
Cash & Cash Equivalents	$1.1B	$918M	$606M	$566M	$642M	$1.1B	$818M	$446M	$1.1B	$442M	$94M	$86M	$72M	$43M	$8M	$3M	$5M	$4M	$13M	$23M	$18M
Total Liabilities	$3.7B	$3.6B	$4.4B	$4.2B	$3.3B	$2.9B	$2.5B	$1.5B	$1.3B	$485M	$119M	$71M	$44M	$38M	$29M	$16M	$16M	$65M	$83M	$70M	$8M
Total Debt (Short + Long-Term)	$1.3B	$1.3B	$2.5B	$2.5B	$2.0B	$1.7B	$1.7B	$1.1B	$1.0B	$361M	$39M	$2M	$5M	$7M	$7M	$0M	$1M	$47M	$63M	$62M	$3M
Total Shareholders' Equity	$3.0B	$2.7B	$2.1B	$2.1B	$2.1B	$2.0B	$1.8B	$883M	$663M	$419M	$284M	$221M	$140M	$84M	$77M	$104M	$61M	($18M)	($19M)	$7M	$57M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DXCM viewer.

Other Companies in Health Care Equipment

EW · Edwards Lifesciences — $48 billion
BDX · Becton Dickinson — $43 billion
IDXX · Idexx Laboratories — $43 billion
RMD · ResMed — $28 billion
GEHC · GE HealthCare — $28 billion
STE · Steris — $21 billion
ZBH · Zimmer Biomet — $18 billion
RVTY · Revvity — $12 billion

← DXC All stocks DXLG →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.